A preoperative serum signature of CEA+/CA125+/ CA19-9≥1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer

International Journal of Cancer

Volumn 136, Issue 9, 2015, Pages 2216-2227

  Liu, Liang ^a,b   Xu, Huaxiang ^a,b   Wang, Wenquan ^a,b   Wu, Chuntao ^a,b   Chen, Yong ^c   Yang, Jingxuan ^d   Cen, Putao ^d   Xu, Jin ^a,b   Liu, Chen ^a,b   Long, Jiang ^a,b   Guha, Sushovan ^d   Fu, Deliang ^e   Ni, Quanxing ^a,b   Jatoi, Aminah ^f   Chari, Suresh ^f   McCleary Wheeler, Angela L ^f   Fernandez Zapico, Martin E ^f   Li, Min ^a,b,d   Yu, Xianjun ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e FUDAN UNIVERSITY   (China)

^f MAYO CLINIC   (United States)

Author keywords

Pancreatic cancer; Predictive potency; Serum signature; Surgical outcome

Indexed keywords

CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; GEMCITABINE; CA 19-9 ANTIGEN; TUMOR MARKER;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; FOLLOW UP; HOSPITAL BED CAPACITY; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; PANCREAS CANCER; PANCREAS RESECTION; PREDICTION; PREOPERATIVE EVALUATION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; BLOOD; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY;

CA-125 ANTIGEN; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84923166273     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29242     Document Type: Article

References (34)

1. Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet 2011;378: 607-20.
2. The NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesTM). The most recent and complete version of the NCCN GuidelinesTM are available at: NCCN.org.
3. Humphris JL, Chang DK, Johns AL, et al. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol 2012;23: 1713-22.
4. Ferrone CR, Finkelstein DM, Thayer SP, et al. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006;24: 2897-902.
5. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26: 3496-502.
6. Reddy SK, Tyler DS, Pappas TN, et al. Extended resection for pancreatic adenocarcinoma. Oncologist 2007;12: 654-63.
7. Hartwig W, Hackert T, Hinz U, et al. Multivisceral resection for pancreatic malignancies: Risk-Analysis and long-Term outcome. Ann Surg 2009;250: 81-7.
8. Takahashi H, Ohigashi H, Ishikawa O, et al. Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival. Ann Surg 2010;251: 461-9.
9. Hartwig W, Werner J, Jager D, et al. Improvement of surgical results for pancreatic cancer. Lancet Oncol 2013;14: E476-85.
10. Biankin AV, Kench JG, Colvin EK, et al. Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology 2009;137: 558-68.
11. Biankin AV, Morey AL, Lee CS, et al. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol 2002;20: 4531-42.
12. Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009;27: 1806-13.
13. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24: 5313-27.
14. Poruk KE, Gay DZ, Brown K, et al. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: Diagnostic and prognostic updates. Curr Mol Med 2013;13: 340-51.
15. Liu L, Xu HX, Wang WQ, et al. Cavin-1 is essential for the tumor-promoting effect of caveolin-1 and enhances its prognostic potency in pancreatic cancer. Oncogene 2014;33: 2728-36.
16. Xu HX, Chen T, Wang WQ, et al. Metabolic tumour burden assessed by F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection. Eur J Nucl Med Mol Imaging 2014;41: 1093-102.
17. Hishinuma S, Ogata Y, Tomikawa M, et al. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg 2006;10: 511-8.
18. Liu L, Zhu XD, Wang WQ, et al. Activation of betacatenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis. Clin Cancer Res 2010;16: 2740-50.
19. Xu HX, Zhu XD, Zhuang PY, et al. Expression and prognostic significance of placental growth factor in hepatocellular carcinoma and peritumoral liver tissue. Int J Cancer 2011;128: 1559-69.
20. Hartwig W, Strobel O, Hinz U, et al. CA19-9 in potentially resectable pancreatic cancer: Perspective to adjust surgical and perioperative therapy. Ann Surg Oncol 2013;20: 2188-96.
21. Chin L, Andersen JN, Futreal PA. Cancer genomics: From discovery science to personalized medicine. Nat Med 2011;17: 297-303.
22. DeOliveira ML, Winter JM, Schafer M, et al. Assessment of complications after pancreatic surgery: A novel grading system applied to 633 patients undergoing pancreaticoduodenectomy. Ann Surg 2006;244: 931-7.
23. Callery MP, Chang KJ, Fishman EK, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: Expert consensus statement. Ann Surg Oncol 2009;16: 1727-33.
24. Kleeff J, Reiser C, Hinz U, et al. Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg 2007;245: 566-72.
25. Yokoyama N, Otani T, Hashidate H, et al. Realtime detection of hepatic micrometastases from pancreatic cancer by intraoperative fluorescence imaging: Preliminary results of a prospective study. Cancer 2012;118: 2813-9.
26. Balzano G, Di Carlo V. Is CA 19-9 useful in the management of pancreatic cancer? Lancet Oncol 2008;9: 89-91.
27. Collisson EA, Sadanandam A, Olson P, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011;17: 500-3.
28. Haridas D, Chakraborty S, Ponnusamy MP, et al. Pathobiological implications of MUC16 expression in pancreatic cancer. PLoS One 2011;6: E26839.
29. Hata S, Sakamoto Y, Yamamoto Y, et al. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol 2012;19: 636-41.
30. Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 2003;138: 951-6.
31. Hernandez J, Mullinax J, Clark W, et al. Survival after pancreaticoduodenectomy is not improved by extending resections to achieve negative margins. Ann Surg 2009;250: 76-80.
32. Bockhorn M, Burdelski C, Bogoevski D, et al. Arterial en bloc resection for pancreatic carcinoma. Br J Surg 2011;98: 86-92.
33. Edge SBB DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual, 7th edn. New York: Springer, 2010.
34. Fuhrman GM, Leach SD, Staley CA, et al. Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group. Ann Surg 1996;223: 154-162.